A kind of sagittol E prepared from Epimedium sagittium and its application
Through the extraction and isolation of Epimedium in Arrow Leaf, arhatidine E was prepared, which solved the problem of insufficient application of Epimedium in disease treatment, especially the protective effect of TGF-β1-induced BEAS-2B cell damage. , realizes the new medicinal value of Epimedium in Arrow Leaf, and has significant economic and social benefits.
Patent Information
- Application Number
- CN202310235867.4
- Authority / Receiving Office
- CN · China
- Patent Type
- Patents(China)
- Current Assignee / Owner
- Filing Date
- 2023-03-13
- Publication Date
- 2024-11-22
- Estimated Expiration
- 2043-03-13
AI Technical Summary
In the prior art, there is little research on the chemical composition of Epimedium in the arrow leaf, and it is difficult to effectively prepare and apply it for disease treatment, especially in drugs that induce BEAS-2B cell damage.
The dried epimedium leaves were crushed, extracted with ethanol heating and reflux, followed by extraction of petroleum ether, dichloromethane, ethyl acetate, and n-butanol, combined with Diaion HP-20 macropore adsorption resin column chromatography, silica gel column, Sephadex LH-20 gel column was separated from HPLC, and the abdolin E was successfully prepared.
Arhatrin E has a protective effect on the damage of BEAS-2B cells inducing TGF-β1, which has achieved its application in treatment, rich raw materials and easy to operate, and has opened up the new medicinal value of Epimedium in Arhat Leaf and has significant Economic and social benefits.
Smart Images

Figure CN116284177B_ABST
Abstract
Description
Technical Field
[0001] The invention relates to medicine, in particular to sagittol glycoside E prepared from Epimedium sagittium and application thereof. Background Art
[0002] Epimedium sagittatum (Sieb. et Zucc.) Maxim, also known as three-branched nine-leaf grass, is a perennial herbaceous plant of the genus Epimedium in the Berberidaceae family. It is one of the medicinal plants of the traditional Chinese medicine Epimedium, which has the effects of tonifying kidney yang, strengthening tendons and bones, and removing rheumatism. It is mainly distributed in Anhui, Jiangxi, Hunan, Hubei and other places. As one of the traditional Chinese medicines for both medicine and food, Epimedium sagittatum is also used in the development of a variety of health products, with huge development potential and application prospects. Epimedium sagittatum has rich pharmacological effects and is widely distributed, but it is currently mainly used to make various types of Chinese patent medicines, and there is little research on its chemical composition.
[0003] Studies have shown that Epimedium sagittatum contains a variety of pharmaceutically active ingredients, but how to prepare them and use them for the treatment of diseases is a technical problem that needs to be seriously addressed. Summary of the invention
[0004] In view of the above situation, in order to overcome the shortcomings of the prior art, the purpose of the present invention is to provide a curaside E prepared from Epimedium sagittatum and its application, which can effectively solve the problem of preparing curaside E from Epimedium sagittatum and realize its application in the preparation of drugs for treating F-β1-induced BEAS-2B cell damage.
[0005] The technical solution provided by the present invention is a kind of scutellarin E, which is prepared from Epimedium sagittatum, and has the molecular structure formula:
[0006]
[0007] The preparation method comprises the following steps: crushing the dried Epimedium sagittatum, extracting by heating and refluxing with ethanol, and concentrating the extract under reduced pressure to obtain a total extract; dissolving and dispersing the total extract with water, and extracting with petroleum ether, dichloromethane, ethyl acetate, and n-butanol in sequence to obtain a petroleum ether fraction, a dichloromethane fraction, an ethyl acetate fraction, an n-butanol fraction, and a remaining water fraction;
[0008] The n-butanol fraction was subjected to Diaion HP-20 macroporous adsorption resin column chromatography, and gradient elution was performed with water and ethanol-water system in sequence. The eluate from each fraction was concentrated under reduced pressure and freeze-dried to obtain fractions Fr.1 to Fr.8;
[0009] Component Fr.5 was loaded onto a silica gel column and gradient eluted with dichloromethane-methanol, sprayed with anisaldehyde-concentrated sulfuric acid for identification, and the same fractions were combined to obtain components Fr.5-1 to Fr.5-8;
[0010] Component Fr.5-3 was dissolved in aqueous methanol, separated by Sephadex LH-20 gel column chromatography, isocratically eluted with 50% methanol by volume, sprayed with anisaldehyde-concentrated sulfuric acid for identification, and the same fractions were combined to obtain components Fr.5-3-1 to Fr.5-3-10;
[0011] Component Fr.5-3-10 was separated by semi-preparative HPLC and the samples with retention time t R = The fraction from 23.7 to 25.0 min was concentrated to dryness to obtain compound curarin E.
[0012] The compound curabioside E has a protective effect on TGF-β1-induced BEAS-2B cell damage, thereby realizing the application of curabioside E in the preparation of a drug for treating TGF-β1-induced BEAS-2B cell damage.
[0013] The invention has abundant raw materials and is easy to operate in the preparation method, and fully utilizes the sagittal epimedium to prepare sagittaloside E, thus developing new medicinal value of the sagittal epimedium, providing technical support for TGF-β1-induced BEAS-2B cell injury drugs, and having significant economic and social benefits. BRIEF DESCRIPTION OF THE DRAWINGS
[0014] Figure 1 It is a molecular structural formula diagram of the compound curabioside E of the present invention.
[0015] Figure 2 The compound of the present invention, curabioside E 1 HNMR (500MHz, CD3OD) spectrum.
[0016] Figure 3 The compound of the present invention, curabioside E 13 CNMR (125MHz, CD3OD) spectrum.
[0017] Figure 4 This is the DEPT135 spectrum of the compound curabioside E of the present invention.
[0018] Figure 5 The compound of the present invention, curabioside E 1 H 1 HCOSY correlation spectra.
[0019] Figure 6 This is the HSQC correlation spectrum of the compound curabioside E of the present invention.
[0020] Figure 7 This is the HMBC correlation spectrum of the compound curabioside E of the present invention.
[0021] Figure 8 This is the HR-ESI-MS spectrum of the compound curabioside E of the present invention.
[0022] Fig. 9 This is the UV spectrum of the compound curabioside E of the present invention.
[0023] Fig.10 This is the IR spectrum of the compound curabioside E of the present invention. DETAILED DESCRIPTION
[0024] The specific implementation modes of the present invention are described in detail below in combination with specific situations.
[0025] The present invention discloses a kind of sargassum glycoside E, which is prepared from Epimedium sagittatum, and has the molecular structure formula:
[0026]
[0027] The preparation method comprises the following steps: crushing 80 kg of dried Epimedium sagittatum, extracting twice with 70% ethanol by heating under reflux, each time with 500 L and 2.5 h, combining the two extracts, and concentrating under reduced pressure to obtain a total extract (8.5 kg); dissolving and dispersing the total extract with water, extracting four times with petroleum ether, dichloromethane, ethyl acetate and n-butanol in sequence, each time with 20 L, to obtain a petroleum ether fraction (150 g), a dichloromethane fraction (2 kg), an ethyl acetate fraction (500 g), a n-butanol fraction (4 kg) and the remaining water fraction;
[0028] The n-butanol fraction was subjected to Diaion HP-20 macroporous adsorption resin column chromatography, and gradient elution was performed in sequence using water, 10%, 20%, 30%, 40%, 50%, 70%, and 95% ethanol-water systems, with the amount used for each elution fraction being 10 times the column volume, and the flow rate being 600 mL / min. The eluate from each fraction was concentrated under reduced pressure and freeze-dried to obtain components Fr.1 (638.5 g), Fr.2 (271.2 g), Fr.3 (413.5 g), Fr.4 (614.9 g), Fr.5 (664.0 g), Fr.6 (459.4 g), Fr.7 (483.0 g), and Fr.8 (106.7 g);
[0029] Component Fr.5 (664.0 g) was loaded onto a 800 g silica gel column and gradient eluted with dichloromethane-methanol volume ratios of 15:1, 10:1, 5:1, and 1:1. The amount used at each gradient elution position was 4 times the column volume. The flow rate was 20 mL / min. Anisaldehyde-concentrated sulfuric acid was used for spray detection. The detection was performed every 200 mL. The same fractions were combined to obtain components Fr.5-1, Fr.5-2, Fr.5-3, Fr.5-4, Fr.5-5, Fr.5-6, Fr.5-7, and Fr.5-8;
[0030] Component Fr.5-3 (5.41 g) was dissolved in 50% aqueous methanol by volume, separated by Sephadex LH-20 gel column chromatography, isocratically eluted with 50% methanol by volume, at a flow rate of 1 mL / min, and sprayed with anisaldehyde-concentrated sulfuric acid for detection, once every 10 mL, and the same fractions were combined to obtain components Fr.5-3-1, Fr.5-3-2, Fr.5-3-3, Fr.5-3-4, Fr.5-3-5, Fr.5-3-6, Fr.5-3-7, Fr.5-3-8, Fr.5-3-9, and Fr.5-3-10;
[0031] Component Fr.5-3-10 was separated by semi-preparative HPLC, using a YMC-Pack ODS-A column with a size of 250×10 mm, a particle size of 5 μm, and a pore size of 12 nm. The mobile phase was a volume ratio of methanol: water = 68:32, a flow rate of 3 mL / min, and the collection retention time was t R = The fraction from 23.7 to 25.0 min was concentrated to dryness to obtain compound curarin E.
[0032] The compound curabioside E has a protective effect on TGF-β1-induced BEAS-2B cell damage, thereby realizing the application of curabioside E in the preparation of a drug for treating TGF-β1-induced BEAS-2B cell damage.
[0033] The compound of the present invention, curaside E, is a compound extracted from Epimedium sagittatum, and has the activity of protecting BEAS-2B cell damage induced by TGF-β1, and realizes the application of curaside E in the preparation of a drug for treating TGF-β1-induced BEAS-2B cell damage. After structural identification and experiments, the effect is very good. The relevant information is as follows:
[0034] 1. Instruments and reagents
[0035] Bruker AVANCEⅢ500 NMR instrument (TMS internal standard) (Bruker) was used for NMR; Nicolet is10 Microscope Spectrometer (Thermo Scientific, USA) was used for infrared spectroscopy; Brukermaxis HD mass spectrometer was used for high-resolution mass spectrometry; Shimadzu UV-2401PC apparatus was used for UV spectroscopy; Waters Alliance series 2695 HPLC system was used for HPLC, equipped with 2998 diode array detector, Empower3 chromatography data workstation, LC50 high pressure preparative liquid chromatograph, UV200 ultraviolet detector [Sepreis (Beijing) Technology Co., Ltd.], YMC-Pack ODS-A chromatographic column (250×10mm.DS-5mm,12mm) (YMC Co., Ltd.); the rest are N-1100 rotary evaporator (Shanghai Ailang Instrument Co., Ltd.), A-1000S water flow vacuum pump (Shanghai Ailang Instrument Co., Ltd.), N-1111 chilled water circulation device (Shanghai Ailang Instrument Co., Ltd.), FDU-2110 freeze dryer (Shanghai Ailang Instrument Co., Ltd.), AB204-N 1 / 10,000 precision analytical balance (METTLER TOLEDO), carbon dioxide 3111 incubator (Thermo, USA), Multiskan MK3 microplate reader (Thermo Fisher, USA), Advantage A10 ultrapure water meter (Sartorius, Germany); BCD-206TAS ultra-low temperature refrigerator (Sartorius, Germany), BT25S 1 / 100,000 precision analytical balance (Sartorius, Germany), ECTGF-Β1E TS100 inverted microscope (Nikon, Japan), Centrifuge-5804R high-speed centrifuge (Eppendorf, Germany), clean bench (Jiangsu Sujing Group), 90-3 two-way timed constant temperature magnetic stirrer (Shanghai Zhenjie Experimental Equipment Co., Ltd.), DZF-6050B vacuum drying oven (Beijing Hengtai Fengke Experimental Equipment Co., Ltd.), HVA-85 high pressure sterilizer (Hirayama, Japan), micropipette (Nichipet EXPLUS), 10 cm culture dish, 96-well culture plate, cryotube (Corning), and common surgical instruments.
[0036] Column chromatography packings were Diaion HP-20, MCI Gel CHP-20 (Mitsubishi Chemical Corporation, Japan), Toyopearl HW-40 (TOSOH Corporation, Japan), Sephadex LH-20 (Parmacia Biotech Corporation), silica gel H (160-200 mesh) used for column chromatography was produced by Qingdao Ocean Chemical Plant, chromatographic reagents were produced by Tianjin Siyou Fine Chemicals Co., Ltd., and analytical reagents were produced by Beijing Chemical Plant and Tianjin Third Chemical Reagent Plant.
[0037] Normal human lung epithelial cells (BEAS-2B) were purchased from the Shanghai Cell Bank of the Academy of Sciences; DMEM high glucose medium (Gibco); fetal bovine serum (Hangzhou Sijiqing Company); ampicillin and streptomycin (Sigma); TGF-β1 (PeproTech); MTT (Beijing Solebold Technology Co., Ltd.); DMSO (Shanghai MacLean Biotechnology Co., Ltd.); water was ultrapure water, and PBS buffer was self-prepared.
[0038] The sagittate Epimedium selected for this experiment was collected from the Fenghui Epimedium planting base in Pingyu, Zhumadian City, Henan Province, and was identified as Sagittate Epimedium of the genus Epimedium by Professor Dong Chengming of the School of Pharmacy of Henan University of Traditional Chinese Medicine.
[0039] 2 Structure identification
[0040] Curarin E, yellow powder, soluble in methanol and other solvents. HR-ESI-MS m / z: 493.1109[M+Na] + (calcd.for C 24 H 22 O 10 Na, 493.1105), the molecular formula of the compound is determined to be C 24 H 22 O 10 UV(CH3OH)λ max (logε):204(4.62), 223(4.45), 244(4.40), 293(4.38), 320(4.32)nm; IR(iTR)ν max cm -1 :3392, 2932, 1661, 1596, 1260, 838cm -1 Equal absorption.
[0041] Table 1 NMR data assignment of scutellarin E (in CD3OD)
[0042]
[0043] Based on the above information, the compound is named as scutellarin E, and its molecular structure is:
[0044]
[0045] 3. Activity Detection
[0046] Take the frozen BEAS-2B cells and thaw them in a 37°C water bath until ice and water coexist. Immediately centrifuge at 1200rpm for 5min. After discarding the supernatant, transfer the cells to a culture dish containing DMEM high-glucose medium with 10% FBS (100kU / L for penicillin and streptomycin), and culture them in a 37°C constant temperature incubator with 5% CO2. When the cells grow to cover 80-90% of the dish, pass them on. Replace the fresh medium every 24 hours. BEAS-2B cells were cultured in a 37°C, 5% CO2 incubator until the logarithmic growth phase. The cell density was 2×10 4 / mL, 200μL per well was inoculated in a 96-well plate, and after 24h, it was divided into a normal group (CON), a model group (TGF-β1, 1ng / mL) and a drug group (10μM+TGF-β1, 1ng / mL). After 24h of culture, 20μL of MTT solution (5mg / mL) was added to each well, and the culture was continued for 4h. The culture medium was carefully aspirated, and 150μL of DMSO was added to each well. The blue-purple crystals in the well were completely dissolved by shaking for 10min. The absorbance value (OD) of each well was measured by a microplate reader at 490nm, and the cell viability was calculated. The MTT method was used to detect the effect of curabioside E on TGF-β1-induced BEAS-2B cell damage. The results showed that curabioside E has potential anti-pulmonary fibrosis activity, and its OD value is 1.060±0.015.
[0047] From the above, it can be seen that the sagittaside E separated from Epimedium sagittae in the present invention has the effect of protecting TGF-β1-induced BEAS-2B cell damage, the raw materials are abundant, and the preparation method is easy to operate, which has opened up the new drug value of Epimedium sagittae, provided technical support for the preparation of drugs for TGF-β1-induced BEAS-2B cell damage, and has significant economic and social benefits.
Claims
1. A scutellarin E is prepared from Epimedium sagittatum, and the molecular structure of the scutellarin E is: The preparation method comprises the following steps: crushing 80 kg of dried Epimedium sagittatum, extracting twice with 70% ethanol by heating and refluxing, each time with 500 L and 2.5 h, combining the two extracts, and concentrating under reduced pressure to obtain a total extract; dissolving and dispersing the total extract with water, extracting four times with petroleum ether, dichloromethane, ethyl acetate and n-butanol in sequence, each time with 20 L, to obtain a petroleum ether fraction, a dichloromethane fraction, an ethyl acetate fraction, an n-butanol fraction and a remaining water fraction; The n-butanol fraction was subjected to Diaion HP-20 macroporous adsorption resin column chromatography, and gradient elution was performed with water, 10%, 20%, 30%, 40%, 50%, 70%, and 95% ethanol-water system in sequence, with the amount used for each elution fraction being 10 times the column volume, and the flow rate being 600 mL / min. The eluate from each fraction was concentrated under reduced pressure, and freeze-dried to obtain components Fr.1, Fr.2, Fr.3, Fr.4, Fr.5, Fr.6, Fr.7, and Fr.8; Component Fr.5 was loaded onto a 800 g silica gel column and gradient eluted with dichloromethane-methanol volume ratios of 15:1, 10:1, 5:1, and 1:
1. The amount used in each gradient elution position was 4 times the column volume. The flow rate was 20 mL / min. Anisaldehyde-concentrated sulfuric acid was used for spray detection. The detection was performed every 200 mL. The same fractions were combined to obtain components Fr.5-1, Fr.5-2, Fr.5-3, Fr.5-4, Fr.5-5, Fr.5-6, Fr.5-7, and Fr.5-8. Component Fr.5-3 was dissolved with 50% aqueous methanol by volume, separated by Sephadex LH-20 gel column chromatography, isocratically eluted with 50% methanol by volume, at a flow rate of 1 mL / min, and detected by spraying with anisaldehyde-concentrated sulfuric acid, once every 10 mL, and the same fractions were combined to obtain components Fr.5-3-1, Fr.5-3-2, Fr.5-3-3, Fr.5-3-4, Fr.5-3-5, Fr.5-3-6, Fr.5-3-7, Fr.5-3-8, Fr.5-3-9, and Fr.5-3-10; Component Fr.5-3-10 was separated by semi-preparative HPLC, using a YMC-Pack ODS-A column with a size of 250×10 mm, a particle size of 5 μm, and a pore size of 12 nm. The mobile phase was a volume ratio of methanol: water = 68:32, a flow rate of 3 mL / min, and the collection retention time was t R = The fraction from 23.7 to 25.0 min was concentrated to dryness to obtain compound curarin E.
2. Use of the curarin E described in claim 1 in the preparation of a drug for treating TGF-β1-induced BEAS-2B cell damage.
